Overview

  • Product nameAnti-NALP1 antibody
    See all NALP1 primary antibodies
  • Description
    Rabbit polyclonal to NALP1
  • SpecificityThis antibody reacts predominantly with DEFCAP.
  • Tested applicationsSuitable for: IHC-P, ELISA, IP, WBmore details
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Synthetic peptide

    WEKGSKKGLLPLSS

    corresponding to C-term of human DEFCAP in both theDEFCAP-L and –S isoforms.

  • Positive control
    • IHC-P: FFPE human cerebral cortex tissue sections.
  • General notes


    Death Effector Filament-forming Ced 4 like Apoptosis Protein (DEFCAP) is a novel apoptotic protein of the mammalian Ced 4 family. It has two isoforms: DEFCAP-L and DEFCAP-S. The deduced amino acid sequences of these two alternately spliced isoforms only differ by 44 amino acids at the C-terminus. DEFCAP contains a caspase recruitment domain (CARD), a domain that with the proper stimulation can recruit caspases to form cytoplasmic structures called death effector filaments, which in turn initiate the apoptotic signaling pathway.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPBS with 0.02% sodium azide
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Primary antibody notesDeath Effector Filament-forming Ced 4 like Apoptosis Protein (DEFCAP) is a novel apoptotic protein of the mammalian Ced 4 family. It has two isoforms: DEFCAP-L and DEFCAP-S. The deduced amino acid sequences of these two alternately spliced isoforms only differ by 44 amino acids at the C-terminus. DEFCAP contains a caspase recruitment domain (CARD), a domain that with the proper stimulation can recruit caspases to form cytoplasmic structures called death effector filaments, which in turn initiate the apoptotic signaling pathway.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab3683 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration. PubMed: 20844241
ELISA Use a concentration of 0.1 - 1 µg/ml.
IP Use 3-5µg for 107 cells.
WB Use a concentration of 0.5 - 2 µg/ml.

Target

  • FunctionAble to form cytoplasmic structures termed death effector filaments. Enhances APAF1 and cytochrome c-dependent activation of pro-caspase-9 and consecutive apoptosis. Stimulates apoptosis through activation of caspase-3. Involved in activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Binds ATP.
  • Tissue specificityWidely expressed. Isoform 1 and isoform 2 are expressed in peripheral blood leukocytes and chronic myelogenous leukemia cell line K-562, followed by thymus, spleen and heart. Also detected in brain, lung, placenta, small intestine, colon, kidney, liver, muscle, testis and epithelial cells. Absent from hematopoietic progenitor cells but expressed upon differentiation of cells into granulocytes and, to a lesser extent, monocytes. In peripheral blood cells, highest levels are found in T-lymphocytes, granulocytes and monocytes. Expression is significantly increased in bone marrow blast cells of some acute leukemia patients but not in solid tumors.
  • Involvement in diseaseGenetic variations in NLRP1 are associated with susceptibility to vitiligo (VTLG) [MIM:193200]. VTLG is a pigmentary disorder of the skin characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. It is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.
    Genetic variations in NLRP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1 (VAMAS1) [MIM:606579]. VAMAS1 is an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
  • Sequence similaritiesBelongs to the NLRP family.
    Contains 1 CARD domain.
    Contains 1 DAPIN domain.
    Contains 6 LRR (leucine-rich) repeats.
    Contains 1 NACHT domain.
  • Cellular localizationCytoplasm. Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CARD 7 antibody
    • CARD7 antibody
    • Caspase recruitment domain protein 7 antibody
    • Caspase recruitment domain-containing protein 7 antibody
    • CLR17.1 antibody
    • Death effector filament forming Ced 4 like apoptosis protein antibody
    • Death effector filament-forming ced-4-like apoptosis protein antibody
    • DEFCAP antibody
    • DEFCAP L/S antibody
    • DKFZp586O1822 antibody
    • KIAA0926 antibody
    • LRR and PYD domains-containing protein 1 antibody
    • NAC alpha/beta/gamma/delta antibody
    • NAC antibody
    • NACHT antibody
    • NACHT leucine rich repeat and PYD containing 1 antibody
    • NACHT leucine rich repeat and PYD pyrin domain containing 1 antibody
    • NACHT leucine rich repeat and pyrin domain containing 1 antibody
    • NACHT LRR and PYD containing protein 1 antibody
    • NALP 1 antibody
    • NALP1 antibody
    • NALP1_HUMAN antibody
    • NLR family pyrin domain containing 1 antibody
    • NLRP 1 antibody
    • NLRP1 antibody
    • NLRP1 protein antibody
    • Nucleotide binding domain and caspase recruitment domain antibody
    • Nucleotide binding oligomerization domain leucine rich repeat and pyrin domain containing 1 antibody
    • Nucleotide-binding domain and caspase recruitment domain antibody
    • PP 1044 antibody
    • PP1044 antibody
    see all

Anti-NALP1 antibody images

  • IHC image of NALP1 staining in human cerebral cortex formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab3683, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-NALP1 antibody (ab3683)

This product has been referenced in:
  • Song F  et al. The Expression Changes of Inflammasomes in the Aging Rat Kidneys. J Gerontol A Biol Sci Med Sci 71:747-56 (2016). Read more (PubMed: 26219846) »
  • Petterson T  et al. Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol 89:177-87 (2011). IHC-P ; Human . Read more (PubMed: 20844241) »

See all 3 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab3683.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"